[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,589,248
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.32
  • Price/Sales 5.70
  • Price/Cash Flow 12.92
  • Price/Book 7.16

Options Overview Details

View History
  • Implied Volatility 31.69% (+1.39%)
  • Historical Volatility 32.75%
  • IV Percentile 66%
  • IV Rank 54.38%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 1) 3.35 (2.58%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 2,926
  • Volume Avg (30-Day) 7,833
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 186,232
  • Open Int (30-Day) 175,043
  • Expected Range 126.55 to 133.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.13
  • Number of Estimates 6
  • High Estimate $2.26
  • Low Estimate $1.84
  • Prior Year $2.47
  • Growth Rate Est. (year over year) -13.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.61 +2.07%
on 07/23/26
140.61 -7.37%
on 07/17/26
+0.64 (+0.49%)
since 07/06/26
3-Month
121.39 +7.30%
on 06/10/26
140.61 -7.37%
on 07/17/26
-6.05 (-4.44%)
since 05/06/26
52-Week
108.46 +20.09%
on 10/02/25
157.29 -17.19%
on 02/11/26
+19.97 (+18.11%)
since 08/06/25

Most Recent Stories

More News
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

GILD : 130.05 (-1.30%)
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

GILD : 130.05 (-1.30%)
Gilead: Q2 Earnings Snapshot

Gilead: Q2 Earnings Snapshot

GILD : 130.05 (-1.30%)
Gilead Sciences Announces Second Quarter 2026 Financial Results

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion ...

GILD : 130.05 (-1.30%)
Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC)– Previously Known as Pheton Holdings Ltd. (PTHL)– Class Action Lawsuit

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a...

GILD : 130.05 (-1.30%)
ITOC : 0.2842 (-2.00%)
PTHL : 0.9023 (+105.16%)
Stocks Set to Open Higher as Oil Sinks on U.S.-Iran Deal Hopes, Jobs Data and Earnings Awaited

September S&P 500 E-Mini futures (ESU26) are up +0.57%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.47% this morning, pointing to a higher open on Wall Street as oil prices sank after U.S....

GOOGL : 359.19 (-0.89%)
UAL : 130.14 (-1.97%)
AAPL : 309.71 (-0.41%)
SNDK : 1,287.92 (-4.63%)
NQU26 : 29,545.25 (-0.24%)
PFE : 25.83 (+0.08%)
SHOP : 146.30 (+1.43%)
MSFT : 495.10 (+1.57%)
TSLA : 319.84 (-0.53%)
FERG : 256.11 (+0.34%)
WDC : 468.50 (-9.76%)
ESU26 : 7,734.75 (-0.19%)
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

GILD : 130.05 (-1.30%)
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges

2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges

TDY : 683.37 (-0.05%)
GILD : 130.05 (-1.30%)
GD : 386.10 (+0.53%)
Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

XLV : 163.39 (-0.47%)
$SPX : 7,712.19 (-0.15%)
GILD : 130.05 (-1.30%)
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19...

GILD : 130.05 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 144.71
2nd Resistance Point 141.25
1st Resistance Point 136.51
Last Price 130.05
1st Support Level 128.31
2nd Support Level 124.85
3rd Support Level 120.11

See More

52-Week High 157.29
Fibonacci 61.8% 138.64
Fibonacci 50% 132.88
Last Price 130.05
Fibonacci 38.2% 127.11
52-Week Low 108.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.